Efficacy and safety profile of roflumilast in a real-world experience

ÇİLLİ A., Bal H., Gunen H.

JOURNAL OF THORACIC DISEASE, vol.11, no.4, pp.1100-1105, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 11 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.21037/jtd.2019.04.49
  • Journal Name: JOURNAL OF THORACIC DISEASE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1100-1105
  • Keywords: Chronic obstructive pulmonary disease (COPD), roflumilast, efficacy, safety, OBSTRUCTIVE PULMONARY-DISEASE, COPD
  • Akdeniz University Affiliated: Yes

Abstract

Background: Roflumilast is the only phosphodiesterase enzyme 4 inhibitor approved in the treatment of chronic obstructive pulmonary disease (COPD) patients with chronic cough and sputum and a history of exacerbations. Real-world studies about the use of roflumilast are limited. Our aim was to assess the efficacy, safety and tolerability of roflumilast in the treatment of stable COPD, in a real-world setting.